HALOZYME REPORTS SECOND QUARTER 2023 FINANCIAL AND OPERATING RESULTS

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 10/25/2026

1. RNG
2. DECK
3. WDC
4. BMY
5. BYD
6. SPOT
7. WCN
8. TSCO
9. BE
10. SPY

Go back to HALOZYME REPORTS SECOND QUARTER 2023 FINANCIAL AND OPERATING RESULTS

Halozyme Therapeutics (HALO) Tops Q2 EPS by 14c, Offers Guidance

August 8, 2023 4:45 PM EDT

Halozyme Therapeutics (NASDAQ: HALO) reported Q2 EPS of $0.74, $0.14 better than the analyst estimate of $0.60. Revenue for the quarter came in at $221 million versus the consensus estimate of $199.95 million.

GUIDANCE:

Halozyme Therapeutics sees FY2023 EPS of $2.65-$2.75, versus the consensus of $2.61.... More